Professor Robert Clarke
MD, FRCP, FFPH, FFPHI, MSc, DCH
Professor of Epidemiology and Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Robert Clarke is a Professor of Epidemiology and Public Health Medicine at the Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health (NDPH), University of Oxford, Honorary Consultant in Public Health Medicine and Scientific Director of the MSc course in Global Health Science and Epidemiology at the University of Oxford. He qualified in clinical medicine in Ireland and worked for 5 years in internal medicine and 4 years in cardiology. After 2 years in clinical pharmacology at Vanderbilt University, Nashville, USA, he joined CTSU in 1991 and specialised in Cardiovascular Epidemiology.
His main research interests are to understand the importance of classical and novel risk factors for cardiovascular diseases. He worked on analyses of observational studies and trials in the UK and meta-analyses of international consortia of observational studies, genome-wide association studies and randomised trials for heart disease and stroke. Over the last decade, his research work has focussed on understanding the causes of stroke and heart disease (ischaemic heart disease and heart failure) in the China Kadoorie Biobank. His research work in CKB includes studies of the diagnostic accuracy, prognosis, treatment, risk prediction and evaluation of genetic and plasma biomarkers for stroke types and ischaemic heart disease and heart failure in CKB and related studies in NDPH and international consortia.
He is a member of the Strategic Oversight Committee for NDPH, the International Steering Committee of CKB, Research Strategy and Management Committee of CKB and Co-chair of International Research Management Committee of CKB.
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Blazing M. et al, (2022), The Lancet, 400, 832 - 845
Systematic review of the utility of the frailty index and frailty phenotype to predict all-cause mortality in older people.
Kim DJ. et al, (2022), Syst Rev, 11
The role of NMR-based circulating metabolic biomarkers in development and risk prediction of new onset type 2 diabetes
BRAGG F. et al, (2022), Scientific Reports
Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study.
Clarke R. et al, (2022), Atherosclerosis, 354, 15 - 22
Sporadic, late-onset, and multistage diseases
WEBSTER A. and CLARKE R., (2022), PNAS Nexus